Creative Planning Halozyme Therapeutics, Inc. Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 46,834 shares of HALO stock, worth $2.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,834

Previous 37,291 25.59%

Holding current value

$2.14 Million

Previous $1.95 Million 37.24%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	BUY	$51.3 - $64.42 $489,555 - $614,760	9,543 Added 25.59%	46,834 $2.68 Million
Q2 2024 Aug 15, 2024	BUY	$37.81 - $52.4 $425,324 - $589,447	11,249 Added 43.2%	37,291 $1.95 Million
Q1 2024 May 10, 2024	BUY	$33.68 - $41.95 $151,829 - $189,110	4,508 Added 20.93%	26,042 $1.06 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $158,369 - $200,101	4,753 Added 28.32%	21,534 $795,000
Q3 2023 Nov 16, 2023	BUY	$36.46 - $44.03 $120,719 - $145,783	3,311 Added 24.58%	16,781 $641,000
Q2 2023 Jul 21, 2023	BUY	$30.28 - $38.74 $407,871 - $521,827	13,470 New	13,470 $485,000
Q4 2022 Feb 10, 2023	BUY	$40.06 - $59.44 $193,249 - $286,738	4,824 New	4,824 $274,000
Q1 2020 May 05, 2020	SELL	$13.9 - $21.83 $148,618 - $233,406	-10,692 Closed	0 $0
Q4 2019 Jan 30, 2020	SELL	$14.93 - $19.53 $343,390 - $449,190	-23,000 Reduced 68.27%	10,692 $190,000
Q2 2019 Jul 26, 2019	SELL	$14.75 - $17.26 $73,750 - $86,300	-5,000 Reduced 12.92%	33,692 $579,000
Q1 2019 Apr 24, 2019	SELL	$13.94 - $17.58 $341,530 - $430,709	-24,500 Reduced 38.77%	38,692 $623,000
Q4 2018 Feb 01, 2019	SELL	$13.33 - $18.66 $7,998 - $11,196	-600 Reduced 0.94%	63,192 $924,000
Q3 2018 Oct 25, 2018	SELL	$16.68 - $18.41 $166,800 - $184,100	-10,000 Reduced 13.55%	63,792 $1.16 Million
Q2 2018 Jul 20, 2018	SELL	$16.87 - $20.3 $185,570 - $223,300	-11,000 Reduced 12.97%	73,792 $1.25 Million
Q1 2018 Apr 18, 2018	SELL	$17.06 - $21.2 $49,303 - $61,268	-2,890 Reduced 3.3%	84,792 $1.66 Million
Q4 2017 Jan 17, 2018	SELL	$16.75 - $20.8 $23,617 - $29,328	-1,410 Reduced 1.58%	87,682 $1.78 Million
Q3 2017 Oct 17, 2017	BUY	$11.76 - $17.4 $1.05 Million - $1.55 Million	89,092	89,092 $1.55 Million

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.36B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Halozyme Therapeutics, Inc. Transaction History